Zeel
Zeel ®
Zeel® has been researched for over 40 years and has been used extensively by patients in approximately 20 countries. Each year, hundreds of thousands of patients are treated with Zeel® to treat degenerative joint disease. Zeel® is produced in Germany by Biologische Heilmittel Heel GmbH and distributed in 20 countries worldwide.
In Greece, Zeel® was granted a marketing authorization as an OTC medicine and is available in pharmacies from the company A.S.K. Pharmaceutical in two easy-to-use formulations: tablet and cream. Zeel® tablet1 is used to relieve the symptoms of pain and inflammation of the joint damage associated with arthropathy. Zeel® cream2 is used topically for the symptomatic treatment of arthropathy pain.
Characteristics
Arnica montana
Sanguinaria canadensis
Rhus toxicodendron
Each individually inhibit both LOX-5 and COX (COX-1 and COX-2)
Solanum dulcamara
Inhibits COX (COX-1 and COX-2), inhibits prostaglandin biosynthesis and PAF induced exocytosis.
Sanguinaria canadensis
Suppresses the proliferative effect of VEGF on endothelial cell line, probably mediated by blocking the VEGF-induced Akt activation.
Suitability
Adults and adolescents above 12 years old
No known drug interactions
Patients with hypersensitivity reactions against conventional treatment
Patients with contraindications to conventional treatment
Option for long term use
Health professionals
- Zeel Leaflet
- Citations
Side Effects Reporting
- How can I report side effects?
